Boehringer submits Pradaxa antidote app; Sanofi's Lantus follow-up nears EMA approval;

> Boehringer Ingelheim has submitted an FDA application for its Pradaxa antidote. Release | More

> The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi's ($SNY) Lantus follow-up, Toujeo, for European approval. Report

> India's Natco Pharma is challenging the patent on Gilead's Sovaldi despite its licensing agreement to make and sell cheap versions of the drug. More (sub. req.)

> AstraZeneca ($AZN) has completed its deal for Actavis' ($ACT) North American respiratory portfolio. Brief

And Finally... Millennials aren't big on big purchases--even cars and houses--but they do like to spend money on health and fitness gadgets. Infographic

Suggested Articles

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.